In a US clinical trial

The majority of IBS-D patients had an abnormal composition of bacteria in the gut1,*

*Data from 93 patients with IBS-D in a prospective TARGET 3 substudy utilizing lactulose breath testing to predict response to XIFAXAN.1

What is gut dysbiosis?

Alterations in specific bacterial groups and microbial community diversity are known as gut dysbiosis. It is an imbalance in the ratio of harmful and helpful bacterial groups.2

Studies show that many patients with IBS-D have a bacterial imbalance in the gut3-5

Bacterial imbalance has been linked to symptoms of IBS-D3,6,7
Effect associated with bacterial imbalance chart
The future

As the body of evidence continues to grow in support of the link between gut dysbiosis and IBS-D, so too does the need for compatible pharmacologic therapies.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.